TY - JOUR
T1 - CD8+ T cell programming by cytomegalovirus vectors
T2 - applications in prophylactic and therapeutic vaccination
AU - Früh, Klaus
AU - Picker, Louis
N1 - Funding Information:
We gratefully acknowledge the large teams of investigators involved in the design, construction and immunological analysis of CMV-based vaccine vectors. Their tireless efforts enable the paradigm-shifting results reviewed here. This work was supported by the National Institutes of Health [grant numbers AI094417, AI054292, DE021291, AI095113, AI117802, AI059457, OD010850, OD011092, GM065794, HHSN272201100013C, AI100645] and the Bill & Melinda Gates Foundation, Seattle, WA [grant numbers OPP1108533 and OPP1133649].
PY - 2017/8
Y1 - 2017/8
N2 - Vectors based on cytomegalovirus (CMV) represent a novel vaccine platform that maintains high frequencies of non-exhausted effector memory T cells in both CMV sero-positive and sero-negative individuals. In non-human primate models, CMV vectored vaccines provide unprecedented protection against simian immunodeficiency virus (SIV). Moreover, CMV vectors can be genetically altered to program highly diverse CD8+ T cell responses that differ in their epitope targeting including conventional, MHC-I restricted CD8+ T cells as well as unconventional CD8+ T cells restricted by MHC class II or non-polymorphic MHC-E. By modifying cytomegaloviral determinants that control unconventional T cell priming it is possible to uniquely tailor the CD8+ T cell response for each individual disease target in order to maximize prophylactic or therapeutic protection.
AB - Vectors based on cytomegalovirus (CMV) represent a novel vaccine platform that maintains high frequencies of non-exhausted effector memory T cells in both CMV sero-positive and sero-negative individuals. In non-human primate models, CMV vectored vaccines provide unprecedented protection against simian immunodeficiency virus (SIV). Moreover, CMV vectors can be genetically altered to program highly diverse CD8+ T cell responses that differ in their epitope targeting including conventional, MHC-I restricted CD8+ T cells as well as unconventional CD8+ T cells restricted by MHC class II or non-polymorphic MHC-E. By modifying cytomegaloviral determinants that control unconventional T cell priming it is possible to uniquely tailor the CD8+ T cell response for each individual disease target in order to maximize prophylactic or therapeutic protection.
UR - http://www.scopus.com/inward/record.url?scp=85024867112&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85024867112&partnerID=8YFLogxK
U2 - 10.1016/j.coi.2017.06.010
DO - 10.1016/j.coi.2017.06.010
M3 - Review article
C2 - 28734175
AN - SCOPUS:85024867112
VL - 47
SP - 52
EP - 56
JO - Current Opinion in Immunology
JF - Current Opinion in Immunology
SN - 0952-7915
ER -